F tier · safety concern
ADAMAX has no molecular identity in any scientific or regulatory source: no PubMed or Europe PMC record, no PubChem entry, no CAS registry number, and no ClinicalTrials.gov study. The person who introduced it states in writing that it is 'a brand new peptide we developed with no human clinical research, or any research of any kind', and the two most detailed structural claims available disagree with each other about where the adamantyl group is even attached.
adamax
ADAMAX is a name used in the research-chemical market rather than an identified compound. Vendors describe it as Semax (Met-Glu-His-Phe-Pro-Gly-Pro) modified with an acetyl group and an adamantane cage, borrowing the adamantyl trick used in the CNTF mimetic P021, but the structural claims are mutually inconsistent and none is corroborated by a chemical registry, a patent, or a publication. There is no scientific literature on ADAMAX at all: a Europe PMC search for the term returns only machine-learning papers using the unrelated Adamax gradient-descent optimiser, and PubChem has no compound of that name.
the explanation
ADAMAX is a brand name, not a known chemical. Sellers say it is the Russian peptide Semax with a extra cage-shaped chemical group bolted on to make it last longer, but they do not agree with each other on where that group goes or what the molecule weighs, and there is no entry for it in any chemical database. No study of any kind has ever been published on it — the person who came up with it says so himself. That means nobody, including the sellers, can tell you what is actually in the vial.
regulatory status
Unidentified substance; unapproved and unlicensed everywhere
There is no licensed medicinal product called ADAMAX in the UK, EU, US or any other jurisdiction; it is not a prescription-only medicine, not a controlled drug, and not a recognised chemical entity, so it is an unlicensed and unidentified substance that cannot lawfully be supplied in the UK for human use and can only be handled as an unclassified laboratory chemical. A ClinicalTrials.gov search returns zero registered studies. It is not a lawful dietary-supplement ingredient anywhere and has no novel-food authorisation in Great Britain. Even the parent molecule it claims descent from is not approved outside the Russian Federation and a small number of neighbouring states, where Semax is registered as a nasal drop; that registration confers nothing on a modified analogue. Because no government health authority has approved it for human therapeutic use, anything sold under this name falls within section S0, Non-Approved Substances, of the WADA Prohibited List — and an athlete cannot even establish what they took, which makes any anti-doping defence impossible.
how it works · proposed mechanism
No mechanism has been established for ADAMAX because no experiment has ever been performed on it. What exists is a mechanistic story inherited from Semax, plus a chemical rationale inherited from the adamantylation strategy used in the CNTF mimetic P021. Both are arguments about what a molecule of this shape might do, not observations of what this material does.
The claimed pharmacology belongs to Semax
Every citation offered for ADAMAX concerns Semax — the ACTH(4-10) analogue Met-Glu-His-Phe-Pro-Gly-Pro developed at the Institute of Molecular Genetics in Moscow — and specifically Ashmarin's and Dolotov's and Grivennikov's work on BDNF and TrkB expression. Semax is a distinct, registry-identified molecule (PubChem CID 9811102, CAS 80714-61-0). Attributing its effects to a chemically modified, unregistered analogue is borrowed evidence in its purest form.
The adamantyl rationale is borrowed from a different programme
Adamantylation as a way to block exopeptidase attack and raise lipophilicity was demonstrated for P021, a completely unrelated CNTF-derived tetrapeptide from Khalid Iqbal's laboratory. One vendor is explicit that the group is 'derived from Peptide P21'. Grafting a modification that worked on one tetrapeptide onto a different heptapeptide changes charge, mass, conformation and receptor fit; it is a hypothesis, not an inference, and it has never been tested.
The structural claims contradict each other
One aggregator states the adamantyl group is conjugated to the N-terminus of Semax, giving C49H73N11O12 at roughly 1000 Da, and marks both figures as approximate or estimated. A large vendor states the opposite — that the adamantyl cap is at the C-terminus, as Ac-MEHFPGP-AGly-NH2, C50H69N11O11S, 1032.23 Da. These describe different molecules with different termini, different masses and, in one case, no sulphur despite Semax beginning with methionine. At most one can be right.
No target, no assay, no data
There is no published receptor binding, no enzyme assay, no cell-based readout, no animal behavioural experiment, no pharmacokinetics and no toxicology for ADAMAX in any species. Its promoter's own description is that it was developed with 'no research of any kind'. A mechanism section for this compound can only describe what has not been done.
what’s reported
evidence shape
7 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
ADAMAX cannot be graded on its evidence because it cannot first be identified. A PubChem name lookup returns nothing while the same lookup for Semax returns CID 9811102, so the negative is a real negative and not a search failure; there is no CAS number, no patent, no reference-reagent catalogue entry and no publication. A Europe PMC search for 'Adamax' returns eighteen records, every one of them a machine-learning paper using the Adamax gradient-descent optimiser — there is no biomedical literature on this substance whatsoever. The two most detailed descriptions available are not merely unsourced but incompatible: one places the adamantyl group at the N-terminus of Semax and gives C49H73N11O12 at approximately 1000 Da with the figures explicitly flagged as estimates, while a major vendor places it at the C-terminus as Ac-MEHFPGP-AGly-NH2, C50H69N11O11S, 1032.23 Da. The clearest statement in the entire record comes from the person who introduced the compound, who writes that it is 'a brand new peptide we developed with no human clinical research, or any research of any kind' — which is both an honest disclosure and a complete description of the evidence base. It is nonetheless sold at 99% claimed purity for human self-administration, and a purity figure is meaningless when the identity of the 99% is undefined.
key published findings
- No chemical registry recognises ADAMAX: PubChem name resolution returns no record, while the control query for Semax returns CID 9811102, and no CAS number has been assigned by any supplier's own admission.
- There is no biomedical literature: a Europe PMC search for the term returns eighteen records, all machine-learning papers using the unrelated Adamax optimisation algorithm, and none about a peptide.
- ClinicalTrials.gov returns zero registered studies, and no patent or reference-reagent catalogue entry exists.
- The two most detailed structural claims are mutually exclusive: N-terminal adamantylation of Semax at C49H73N11O12 and roughly 1000 Da (explicitly labelled approximate and estimated) versus C-terminal 3-aminoadamantane-1-carboxamide capping of N-acetyl Semax amide at C50H69N11O11S and 1032.23 Da.
- All pharmacology offered in support is Semax literature — Ashmarin 1995, Dolotov 2006, Grivennikov 2008 on BDNF and TrkB — concerning a different, registry-identified molecule (CAS 80714-61-0).
- The compound's own promoter states in writing that it was developed with 'no human clinical research, or any research of any kind'.
limitations of the evidence
- No molecular identity can be established from any credible source, so no property of the substance — potency, stability, purity, impurity profile — can be meaningfully specified or checked.
- Zero studies of any kind exist: no in vitro assay, no animal experiment, no pharmacokinetics, no toxicology, no human exposure.
- Because different vendors claim different structures, two products sold under this name need not contain the same molecule, and a certificate of analysis has no reference standard to be analysed against.
- All cited pharmacology belongs to Semax, a different molecule; even Semax's own human evidence base is largely Russian-language and methodologically limited, so the borrowed foundation is itself weak.
- The adamantyl modification is assumed to preserve Semax's activity while extending its half-life, but adding a large lipophilic cage to a seven-residue peptide can equally abolish receptor engagement; no experiment has tested which happened.
- No storage, solubility, stability or handling data can be validated for a substance whose composition is unknown.
documented safety signals
- There is no safety data of any kind, in any species, for this substance — and unlike a merely untested compound, the absence of a defined structure means no read-across, no impurity assessment and no toxicological prediction is possible even in principle.
- Identity risk is the primary hazard: material sold under this name has no reference standard, no CAS number and no agreed structure, so the contents of a vial cannot be verified by the buyer, the seller, or a testing laboratory.
- Adding a bulky lipophilic adamantane group is intended to prolong exposure; if it succeeds, it also prolongs exposure to any off-target activity and to any impurity, with no toxicokinetic data to bound the risk.
- The parent molecule Semax is a melanocortin-family ACTH(4-10) analogue, a class with neuroendocrine activity, and is not approved for human use in the UK, EU or US in any form.
- Absence of reported harm reflects the complete absence of study and of post-market surveillance, not evidence of safety.
identity
| full name | ADAMAX — a research-market trade name with no established molecular identity; most commonly claimed to be an adamantyl-modified N-acetyl Semax amide |
| category | Cognitive |
| modality | other |
laboratory handling
| storage | Because the substance has no established identity, no compound-specific handling guidance can be given. Material supplied as a lyophilised powder under this name should be treated as an unclassified research chemical: keep the sealed vial frozen, desiccated and protected from light, equilibrate to room temperature before opening, and avoid repeated freeze-thaw of any reconstituted solution. If a methionine-containing sequence is present as claimed, solutions would be oxidation-sensitive and should not be stored in air-exposed containers. For laboratory use only. |
| solubility | No solubility data exist and none can be specified without a defined structure. Laboratory handling information only. |
| co-studied with | No combination data exist because no data of any kind exist. Vendor stacking suggestions pairing it with other nootropic peptides are unsupported by any experiment and are additionally unsafe to reason about, since the identity of the substance being combined is unknown. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
7 citedPubChem, National Center for Biotechnology Information · 2026 · official
Europe PMC, EMBL-EBI · 2026 · official
U.S. National Library of Medicine, ClinicalTrials.gov · 2026 · official
World Anti-Doping Agency · 2025 · official
jaycampbell.com (commercial blog) · 2026 · tertiary
Behemoth Labz (vendor product page) · 2026 · tertiary
Wikipep (peptide aggregator wiki) · 2026 · tertiary
Sources marked tertiary or press release are the weakest citations on this page.
others in Cognitive